6 Reasons Early-Phase Oncology Trials Fail

Early Phase, Hematology & Oncology, Oncology

Only 15% of oncology drugs that get started in clinical trials reach phase III studies, and the likelihood of approval for any new anticancer drug entering clinical trials is just over 5%. But why is the success rate so dismal? In this eBook, we’ll review the common reasons that these trials fail (and how you can take steps to ensure success).


4 Real-World Evidence Trends

Real World Evidence

We’re in a transformative period for Real-World Evidence in which increased stakeholder acceptance is being achieved through advances in technology, improved methodology, regulatory endorsement, and an overall recognition of the importance of the real-world in drug development and commercialization. In this eBook, Worldwide unlocks for trends to consider before you take the first step.